BloodSource has announced the opening of its 19th donor center to help meet the increasing demand for plasma-based medicines used in the treatment of more than 80 different medical conditions including neurological diseases,immune deficiencies, and bleeding disorders such as Hemophilia etc. The center will be located in Granite Bay, CA.
“We are experiencing a worldwide shortage of plasma,” stated Mike Fuller CEO of Bloodsource.”There is an increasing need to help patients that rely on plasma-derived medicines for survival. The launch of our new source plasma donor center is a part of ongoing efforts to grow our longstanding mission of providing blood and services to those in need and to specifically address this global concern.”
“People who have immune deficiencies count on specific medicines to allow them to live full and productive lives,” added Bonnie Doak, who was diagnosed with two immune deficiencies. “These therapies are not possible without plasma donors. When I was 40 years old, I was given two years to live. But 30 years later, I’m still standing and grateful to be here.”
In addition, BloodSource will also host the inaugural Global Symposium on the Future for Blood and Plasma Donations.The event is being held in collaboration with the International Plasma Fractionation Association (IPFA) and Blood Centers of America Inc. September in Sacramento, and will “identify and address the increasing global patient need for essential life saving plasma-based therapies, and draw colleagues from blood banking, patient and donor organizations, and regulatory authorities involved in policies to secure and increase the global supply of plasma.” Among the international roster of guest speakers will be representatives from India’s PlasmaGen BioSciences Pvt Ltd., the US’s Rotary International, Egypt’s Shabrawishi Hospital (Egypt), South African National Blood Service,UNC Hemoderivados of Argentina, and the Federation of Hemophilia/A-PLUS from the United States and Spain. Topics covered during the Symposium include clinical developments in plasma product use, quality management of plasma, optimizing plasma collection and economics, industry developments in support of blood establishments, and more.
